Cargando…
Bronchial asthma: is personalized therapy on the horizon?
In the last years there is an increasing trend towards personalized medicine for patients with asthma. This is due to the availability of novel specific therapies. These new compounds are supposed to be used in well-defined patient groups, which are likely to respond to these interventions. In addit...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Urban & Vogel
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479476/ https://www.ncbi.nlm.nih.gov/pubmed/26120534 http://dx.doi.org/10.1007/s40629-014-0028-y |
| _version_ | 1782378016562741248 |
|---|---|
| author | Taube, Christian |
| author_facet | Taube, Christian |
| author_sort | Taube, Christian |
| collection | PubMed |
| description | In the last years there is an increasing trend towards personalized medicine for patients with asthma. This is due to the availability of novel specific therapies. These new compounds are supposed to be used in well-defined patient groups, which are likely to respond to these interventions. In addition to already used anti-IgE, novel monoclonal antibodies such as anti-IL-5 and anti-IL-13 are becoming available. Currently clinical trials are ongoing to identify which patient population will respond to these novel therapies. |
| format | Online Article Text |
| id | pubmed-4479476 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Urban & Vogel |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-44794762015-06-26 Bronchial asthma: is personalized therapy on the horizon? Taube, Christian Allergo J Int Review Article In the last years there is an increasing trend towards personalized medicine for patients with asthma. This is due to the availability of novel specific therapies. These new compounds are supposed to be used in well-defined patient groups, which are likely to respond to these interventions. In addition to already used anti-IgE, novel monoclonal antibodies such as anti-IL-5 and anti-IL-13 are becoming available. Currently clinical trials are ongoing to identify which patient population will respond to these novel therapies. Urban & Vogel 2014-11-06 2014 /pmc/articles/PMC4479476/ /pubmed/26120534 http://dx.doi.org/10.1007/s40629-014-0028-y Text en © Urban & Vogel 2014 |
| spellingShingle | Review Article Taube, Christian Bronchial asthma: is personalized therapy on the horizon? |
| title | Bronchial asthma: is personalized therapy on the horizon? |
| title_full | Bronchial asthma: is personalized therapy on the horizon? |
| title_fullStr | Bronchial asthma: is personalized therapy on the horizon? |
| title_full_unstemmed | Bronchial asthma: is personalized therapy on the horizon? |
| title_short | Bronchial asthma: is personalized therapy on the horizon? |
| title_sort | bronchial asthma: is personalized therapy on the horizon? |
| topic | Review Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479476/ https://www.ncbi.nlm.nih.gov/pubmed/26120534 http://dx.doi.org/10.1007/s40629-014-0028-y |
| work_keys_str_mv | AT taubechristian bronchialasthmaispersonalizedtherapyonthehorizon |